FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Apple Explores India for iPhone Chip Assembly as Manufacturing Push Accelerates 
SUPERFORTUNE Launches AI-Powered Mobile App, Expanding Beyond Web3 Into $392 Billion Metaphysics Market 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand 
Biren Technology Targets Hong Kong IPO to Raise $300 Million Amid China’s AI Chip Push 
Robinhood Expands Sports Event Contracts With Player Performance Wagers 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
EU Signals Major Shift on 2035 Combustion Engine Ban Amid Auto Industry Pressure 
iRobot Files for Chapter 11 Bankruptcy Amid Rising Competition and Tariff Pressures 
Korea Zinc to Build $7.4 Billion Critical Minerals Refinery in Tennessee With U.S. Government Backing 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
SOUTH SAN FRANCISCO, Calif., Sept. 07, 2016 -- Mateon Therapeutics, Inc. (Nasdaq:MATN), a clinical-stage biopharmaceutical company developing vascular disrupting agents for the treatment of orphan oncology indications, today announced it will be featured as a presenting company at the 18th Annual Rodman & Renshaw Global Investment Conference. Mateon’s presentation will take place on Monday, September 12, 2016 at 12:30 p.m. Eastern time in the Louis Salon at the Lotte New York Palace Hotel.
To listen to a live webcast of the presentation, please visit the Company's website, www.mateon.com. Under the "Investors & News" tab, select the link to "Events & Presentations." A replay of the webcast will be available at this same location for a period of time following the conclusion of the live event.
About Mateon
Mateon Therapeutics, Inc. is a biopharmaceutical company seeking to realize the full potential of vascular targeted therapy (VTT) in oncology. VTT includes vascular disrupting agents (VDAs) such as the investigational drugs that Mateon is developing, and anti-angiogenic agents (AAs), a number of which are FDA-approved and widely used in cancer treatment. These two approaches have distinct yet complementary mechanisms of action.
At Mateon, we believe that we can significantly improve cancer therapy by employing these two complementary approaches simultaneously. When utilized this way, VDAs obstruct existing blood vessels in the tumor leading to significant central tumor cell death while AAs prevent the formation of new tumor blood vessels.
Mateon is committed to leveraging our intellectual property and the product development expertise of our highly skilled management team to enable VTT to realize its true potential and to bring much-needed new therapies to cancer patients worldwide.
CONTACT for investors and media: [email protected] 650-635-7000
